XDR-TB: A Special News Recap Discussion
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
In this segment, Dr. Pavia examines the case of patient Andrew Speaker, who is publicly struggling with Extensively Drug-Resistant (XDR) Tuberculosis, and the state of American Public Health Care Systems responding to the threat of transmission with this dangerous infectious disease. The interview clarifies distinctions between XDR-Tuberculosis and the more classical Multi-Drug-Resistant Tuberculosis, and follows with a discussion on some of the challenges faced by those organizations working to prevent and control spread of major infectious diseases.
Overview
In this segment, Dr. Pavia examines the case of patient Andrew Speaker, who is publicly struggling with Extensively Drug-Resistant (XDR) Tuberculosis, and the state of American Public Health Care Systems responding to the threat of transmission with this dangerous infectious disease. The interview clarifies distinctions between XDR-Tuberculosis and the more classical Multi-Drug-Resistant Tuberculosis, and follows with a discussion on some of the challenges faced by those organizations working to prevent and control spread of major infectious diseases.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
Evolving Our View of the Coagulation Cascade and Stroke Management
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
M3: Managing the Cardiometabolic Risk in MASH
Maximizing Adherence and Persistence via Patient Engagement
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?